DALLAS, March 27, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced financial results for the fourth quarter (“Q4 2023”) and full year (“FY 2023”) ended December 31, 2023 and provided an update on its ongoing business activities.
“Spectral AI achieved much in 2023, and our progress along multiple fronts has continued into 2024,” said Peter M. Carlson, Chief Executive Officer. “The team’s achievements to date, and those on the horizon, are the result of a 10-year record of success in delivering on a promise to develop and commercialize our proprietary AI-Driven DeepView™ System wound healing assessment platform, a technology that we believe can help change the standard of care while delivering value across the healthcare ecosystem. We expect to realize our first commercial product revenue in the second half of this year. Given the pace of our product development and clinical activities in the US and internationally, we believe that we are on the proper path to generate commercial revenue across four separate DeepView™ System platforms covering burn and diabetic foot ulcer (DFU) within the next three years.
“We have a well-defined business focus for 2024 based on the evolution of our DeepView™ System from clinical stage to commercialization. We will continue to advance our research and development work under current US Government contracts for our DeepView™ System burn indication and plan to submit regulatory filings for the approval of this indication in the US in the first half of 2025. We are pursuing the commercialization of our DeepView™ System for the assessment of DFU in the US and the UK, and expect to submit regulatory filings for the approval of this indication in the US and UK in 2024. Our recent financing agreements in combination with the multi-year, non-dilutive funding provided by our US Government contracts provides us with a sound financial foundation to pursue these objectives. “
2023-2024 SELECT BUSINESS HIGHLIGHTS
Government Funding
First Commercial Product Revenue
Regulatory
Clinical Trials
Product Development
Corporate
2023 FINANCIAL RESULTS OVERVIEW
All comparisons to Q4 2023 and FY 2023 are to the comparable periods ended December 31, 2022, unless otherwise stated.
Research & Development Revenue
Research & Development Revenue1 for Q4 2023 was $5.3 million compared to $6.1 million, primarily due to the implementation of the new BARDA PBS contract, executed in September 2023.
For FY 2023, Research & Development revenue was $18.1 million compared to $25.4 million, reflecting a decrease in activity due to the completion of work under the BARDA Burn II contract, partially offset by the commencement of work under the new BARDA PBS contract.
Gross Margin
Gross margin for Q4 2023 was 46.1% compared to 41.1%.
For FY 2023, gross margin rose to 43.6% from 42.7%. The improvement in gross margin for both periods reflected the commencement of work under the BARDA PBS contract, which carries a higher reimbursement rate than the prior BARDA Burn II contract.
General & Administrative Expense
General & administrative expenses in Q4 2023 were $5.4 million compared to $4.3 million.
For FY 2023, general & administrative expenses rose to $20.9 million from $13.5 million. The increase for both periods was the result of increased headcount required to support our organizational growth, and higher costs associated with an increase in non-revenue generating R&D activities.
Net Loss
Net loss for Q4 2023 was $(3.5) million, or $(0.22) per share, compared to a net loss of $(1.7) million, or $(0.13) per share, for Q4 2022.
For FY 2023, the net loss was $(20.9) million, or $(1.48) per share, compared to a net loss of $(2.9) million, or $(0.22) per share, for FY 2022.
Net loss for the 2023 period included $8.3 million of non-recurring transaction costs associated with the consummation of the Company’s business combination that resulted in its Nasdaq listing; there were no such costs incurred in 2022.
Cash
As of December 31, 2023, cash was $4.8 million and the Company had no long-term debt.
During the first quarter of 2024, the Company enhanced its financial position, as follows:
1Research and Development Revenue consisted primarily of funding from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services.
2024 Guidance
The Company is reiterating its revenue guidance of approximately $28.0 million for FY 2024. Financial guidance for FY 2024 does not reflect expected contributions from the sale of the DeepView™ System for burn in the UK beginning in the second half of 2024 or any additional material financial contributions that may result from the commercialization of our DeepView™ System.
CONFERENCE CALL
The Company will host a conference call today at 5:00 pm Eastern Time to discuss these results.
Investors interested in participating in the live call can dial:
A simultaneous webcast of the call may be accessed online from the Events & Presentations section of the Investor Relations page of the Company’s website at https://investors.spectral-ai.com/news-events/events
About Spectral AI
Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns and diabetic foot ulcers. The Company is working to revolutionize the management of wound care by “Seeing the Unknown®” with its DeepView System. DeepView is a predictive device that offers clinicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal of exceeding the current standard of care in the future, DeepView is expected to provide faster and more accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs. For more information about DeepView, visit www.spectral-ai.com.
Forward-Looking Statements
Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s strategy, plans, objectives, initiatives and financial outlook. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements.
These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward-looking statements.
Investors should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” sections of the Company’s filings with the SEC, including the Registration Statement and the other documents filed by the Company. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements.
Investors:
The Equity Group
Devin Sullivan
Managing Director
This email address is being protected from spambots. You need JavaScript enabled to view it.
Conor Rodriguez
Analyst
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media:
Russo Partners
David Schull
Russo Partners
(858) 717-2310
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Spectral AI, Inc. | |||||||
| Condensed Consolidated Balance Sheets | |||||||
| (in thousands, except share and per share data) | |||||||
| December 31, | December 31, | ||||||
| 2023 | 2022 | ||||||
| Assets | |||||||
| Current assets: | |||||||
| Cash | $ | 4,790 | $ | 14,174 | |||
| Accounts receivable, net | 2,346 | 2,294 | |||||
| Inventory | 230 | - | |||||
| Unbilled revenue | - | 618 | |||||
| Deferred offering costs | 283 | - | |||||
| Prepaid expenses | 1,452 | 331 | |||||
| Other current assets | 801 | 270 | |||||
| Total current assets | 9,902 | 17,687 | |||||
| Non-current assets: | |||||||
| Property and equipment, net | 12 | 21 | |||||
| Right-of-use assets | 778 | 1,008 | |||||
| Total Assets | $ | 10,692 | $ | 18,716 | |||
| Commitments and contingencies (Note 8) | |||||||
| Liabilities and Stockholders’ Equity (Deficit) | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 2,683 | $ | 2,759 | |||
| Accrued expenses | 4,300 | 2,631 | |||||
| Deferred revenue | 2,311 | - | |||||
| Lease liabilities, short-term | 853 | 680 | |||||
| Notes payable | 436 | 175 | |||||
| Warrant liabilities | 1,818 | 129 | |||||
| Total current liabilities | 12,401 | 6,374 | |||||
| Lease liabilities, long-term | - | 346 | |||||
| Total Liabilities | 12,401 | 6,720 | |||||
| Stockholders’ Equity (Deficit) | |||||||
| Preferred stock ($0.0001 par value); 1,000,000 shares authorized; no shares issued and outstanding as of December 31, 2023 and December 31, 2022 | - | - | |||||
| Common stock ($0.0001 par value); 80,000,000 shares authorized; 16,294,935 and 13,170,148 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively | 2 | 1 | |||||
| Additional paid-in capital | 31,065 | 23,929 | |||||
| Accumulated other comprehensive income | 12 | - | |||||
| Accumulated deficit | (32,788 | ) | (11,934 | ) | |||
| Total Stockholders’ Equity (Deficit) | (1,709 | ) | 11,996 | ||||
| Total Liabilities and Stockholders’ Equity (Deficit) | $ | 10,692 | $ | 18,716 | |||
| Spectral AI, Inc. | ||||||||||||||||||||
| Condensed Consolidated Statements of Operations | ||||||||||||||||||||
| (in thousands, except share and per share data) | ||||||||||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | |||||||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||||||
| Research and development revenue | $ | 5,287 | $ | 6,096 | $ | 18,056 | $ | 25,368 | ||||||||||||
| Cost of revenue | (2,851 | ) | (3,588 | ) | (10,176 | ) | (14,531 | ) | ||||||||||||
| Gross profit | 2,436 | 2,508 | 7,880 | 10,837 | ||||||||||||||||
| Operating costs and expenses: | ||||||||||||||||||||
| General and administrative | 5,365 | 4,277 | 20,864 | 13,484 | ||||||||||||||||
| Total operating costs and expenses | 5,365 | 4,277 | 20,864 | 13,484 | ||||||||||||||||
| Operating loss | (2,929 | ) | (1,769 | ) | (12,984 | ) | (2,647 | ) | ||||||||||||
| Other income (expense): | ||||||||||||||||||||
| Net interest income | 44 | 20 | 172 | 21 | ||||||||||||||||
| Change in fair value of warrant liability | (669 | ) | 7 | 335 | 57 | |||||||||||||||
| Foreign exchange transaction loss, net | (13 | ) | 18 | (24 | ) | (237 | ) | |||||||||||||
| Transaction costs | - | - | (8,342 | ) | - | |||||||||||||||
| Total other expense, net | (638 | ) | 45 | (7,859 | ) | (159 | ) | |||||||||||||
| Loss before income taxes | (3.567 | ) | (1,724 | ) | (20,843 | ) | (2,806 | ) | ||||||||||||
| Income tax provision | 21 | (15 | ) | (11 | ) | (106 | ) | |||||||||||||
| Net loss | $ | (3,546 | ) | $ | (1,739 | ) | $ | (20,854 | ) | $ | (2,912 | ) | ||||||||
| Net loss per share of common stock | ||||||||||||||||||||
| Basic and Diluted | $ | (0.22 | ) | $ | (0.13 | ) | $ | (1.48 | ) | $ | (0.22 | ) | ||||||||
| Weighted-average common shares outstanding | ||||||||||||||||||||
| Basic and Diluted | 16,097,399 | 13,164,086 | 14,087,586 | 13,136,965 | ||||||||||||||||
| Other comprehensive income: | ||||||||||||||||||||
| Foreign currency translation adjustments | $ | 12 | $ | - | $ | 12 | $ | - | ||||||||||||
| Total comprehensive loss | $ | (3,534 | ) | $ | (1,739 | ) | $ | (20,842 | ) | $ | (2,912 | ) | ||||||||
| Spectral AI, Inc. | |||||||
| Condensed Consolidated Statements of Cash Flows | |||||||
| (in thousands, except share and per share data) | |||||||
| Year Ended December 31, | |||||||
| 2023 | 2022 | ||||||
| Cash flows from operating activities: | |||||||
| Net loss | $ | (20,854 | ) | $ | (2,912 | ) | |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||||
| Depreciation expense | 9 | 11 | |||||
| Stock-based compensation | 1,243 | 1,155 | |||||
| Amortization of right-of-use assets | 713 | 557 | |||||
| Issuance of shares for transaction costs | 4,350 | - | |||||
| Change in fair value of warrant liabilities | (335 | ) | (57 | ) | |||
| Changes in operating assets and liabilities: | |||||||
| Accounts receivable | (52 | ) | (859 | ) | |||
| Inventory | (230 | ) | - | ||||
| Unbilled revenue | 618 | (547 | ) | ||||
| Prepaid expenses | (377 | ) | 615 | ||||
| Other assets | (404 | ) | 40 | ||||
| Accounts payable | (935 | ) | 1,345 | ||||
| Accrued expenses | 1,359 | 51 | |||||
| Deferred revenue | 2,311 | - | |||||
| Lease liabilities | (656 | ) | (561 | ) | |||
| Net cash used in operating activities | (13,240 | ) | (1,162 | ) | |||
| Cash flows from financing activities: | |||||||
| Proceeds from issuance of common stock for Equity Raise | 3,351 | - | |||||
| Cash received in Business Combination | 660 | - | |||||
| Payments for notes payable | (483 | ) | (785 | ) | |||
| Stock option exercises | 316 | - | |||||
| Net cash provided by (used in) financing activities | 3,844 | (785 | ) | ||||
| Effect of exchange rate changes on cash | 12 | - | |||||
| Net decrease in cash | (9,384 | ) | (1,947 | ) | |||
| Cash, beginning of period | 14,174 | 16,121 | |||||
| Cash, end of period | $ | 4,790 | $ | 14,174 | |||
| Last Trade: | US$1.88 |
| Daily Change: | 0.10 5.56 |
| Daily Volume: | 1,552,592 |
| Market Cap: | US$36.660M |
December 12, 2024 December 09, 2024 December 02, 2024 November 21, 2024 November 19, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
